Skip to main content

Table 2 Antibiotic therapy administered within 72 h of admission

From: Low frequency of community-acquired bacterial co-infection in patients hospitalized for COVID-19 based on clinical, radiological and microbiological criteria: a retrospective cohort study

 

Total study population

Co-infection unlikely

Co-infection possible/probable

Total number of patients

281 (100)

233 (100)

38 (100)

Patients receiving systemic antibiotic therapy

228 (81.1)

182 (78.1)

36 (94.7)

Ceftriaxone/cefotaxime monotherapy*

167 (59.4)

136 (58.4)

24 (63.2)

Ceftriaxone/cefotaxime + quinolone

25 (8.9)

17 (7.3)

5 (13.2)

Other combination therapy**

24 (8.5)

19 (8.2)

5 (13.2)

Amoxicillin monotherapy

6 (2.1)

4 (1.7)

2 (5.3)

Other monotherapy***

6 (2.1)

6 (2.6)

0 (0)

  1. Numbers are n (%)
  2. *Including patients in whom both amoxicillin + ceftriaxone was given
  3. **Other combination therapy: a combination of beta-lactam antibiotics, combination of beta-lactam antibiotic with macrolide/quinolone/glycopeptide/cotrimoxazole/metronidazole or combinations of three different antibiotic classes
  4. ***Other monotherapy: other beta-lactam antibiotics (e.g. flucloxacillin or ceftazidime) or any of the other antibiotic classes (e.g. nitrofurantoin, cotrimoxazole)